Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion
Journal of Drugs in Dermatology · 2023
DOI: 10.36849/jdd.7367 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Drugs in Dermatology, 2023. Verfasst von James Del Rosso und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatologic Agents, Psoriasis, Nicotinic Acids.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Del Rosso, J., Han, G., Armstrong, A., Lewitt, G. M., & Jacobson, A. (2023). Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7367
Vancouver
Del Rosso J, Han G, Armstrong A, Lewitt GM, Jacobson A. Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7367
BibTeX
@article{DelRosso2023,
author = {Del Rosso, James and Han, George and Armstrong, April and Lewitt, G Michael and Jacobson, Abby},
title = {Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion},
journal = {Journal of Drugs in Dermatology},
year = {2023},
doi = {10.36849/jdd.7367}
}
EUVIMED